A Phase 2 Study of Interferon Beta-1a (Avonex®) in Ulcerative Colitis

Completed · Phase 2 · Has a placebo group

Conditions studied: Active Ulcerative Colitis

In brief

The primary objective of the study is to evaluate the clinical activity of interferon beta-1a in participants with moderate to severe ulcerative colitis (UC). Secondary objectives of this study are to determine (i) the safety and tolerability of interferon beta-1a in participants with moderate to severe UC, and (ii) the percentage of participants, with a decrease in the Simple Clinical Colitis Activity Index (SCCAI) score of ≥3 points at Week 8.

Key facts

Study ID: NCT00616434
Run by: Biogen
People needed: 123
Starts: 2008-05-01
Expected to finish: 2010-03-01
Last updated by the study team: 2014-08-13

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

Where it is running

Investigator — Birmingham, Alabama, United States
Investigator — Lakewood, Colorado, United States
Investigator — Bristol, Connecticut, United States
Investigator — Wellesley Hills, Massachusetts, United States
Investigator — Oklahoma City, Oklahoma, United States
Investigator — Calgary, Alberta, Canada
Investigator — Kelowna, British Columbia, Canada
Investigator — Winnipeg, Manitoba, Canada
Investigator — Hradec Králové, Czechia
Investigator — Ostrava, Czechia
Investigator — Parbudice, Czechia
Investigator — Prague, Czechia
Investigator — Slaný, Czechia
Investigator — Teplice, Czechia
Investigator — Budapest, Hungary
Investigator — Eger, Hungary
Investigator — Szeged, Hungary
Investigator — Székesfehérvár, Hungary
Investigator — Lublin, Poland
Investigator — Pruszków, Poland
Investigator — Sopot, Poland
Investigator — Torun, Poland
Investigator — Warsaw, Poland
Investigator — Wroclaw, Poland
Investigator — Kazan', Russia

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.